These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 15737773

  • 21. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Laws HJ, Calaminus G, Göbel U.
    Cancer; 2005 Apr 15; 103(8):1759; author reply 1760. PubMed ID: 15717299
    [No Abstract] [Full Text] [Related]

  • 22. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Fioredda F, Giacchino M, Castagnola E.
    Cancer; 2005 Apr 15; 103(8):1758-9; author reply 1760. PubMed ID: 15717298
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.
    Ciarlet M, He S, Lai S, Petrecz M, Yuan G, Liu GF, Mikviman E, Heaton PM, Panzer F, Rose T, Koller DY, Van Damme P, Schödel F.
    Pediatr Infect Dis J; 2009 Mar 15; 28(3):177-81. PubMed ID: 19209092
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Reactogenicity and immunogenicity of a new measles-mumps-rubella vaccine containing RIT 4385 mumps virus strain in healthy Turkish children.
    Kanra G, Ceyhan M, Ozmert E.
    Turk J Pediatr; 2000 Mar 15; 42(4):275-7. PubMed ID: 11196741
    [Abstract] [Full Text] [Related]

  • 27. A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years.
    Marshall H, Nolan T, Roberton D, Richmond P, Lambert S, Jacquet JM, Schuerman L.
    Vaccine; 2006 Aug 28; 24(35-36):6120-8. PubMed ID: 16822597
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH, Thein SA, Aye A, Han HH, Bock HL, David MP, Schuerman L.
    Pediatr Infect Dis J; 2006 Aug 28; 25(8):706-12. PubMed ID: 16874170
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effectiveness of a seventh grade school entry vaccination requirement--statewide and Orange County, Florida, 1997-1998.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 1998 Sep 04; 47(34):711-5. PubMed ID: 9746399
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine.
    Meriste S, Lutsar I, Tamm E, Willems P.
    Scand J Infect Dis; 2006 Sep 04; 38(5):350-6. PubMed ID: 16709537
    [Abstract] [Full Text] [Related]

  • 37. Adolescent vaccination: coverage achieved by ages 13-15 years, and vaccinations received as recommended during ages 11-12 years, National Health Interview Survey 1997-2003.
    McCauley MM, Stokley S, Stevenson J, Fishbein DB.
    J Adolesc Health; 2008 Dec 04; 43(6):540-7. PubMed ID: 19027641
    [Abstract] [Full Text] [Related]

  • 38. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
    Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt HJ.
    Vaccine; 2006 May 29; 24(22):4727-36. PubMed ID: 16616973
    [Abstract] [Full Text] [Related]

  • 39. [Studies on the safety and immunogenicity of lyophilized live attenuated measles-mumps-rubella combined vaccine].
    Liu G, Fang H, Feng Z, Guo W, Dong C, Zhang W, Ze W.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2002 Dec 29; 23(6):435-7. PubMed ID: 12667354
    [Abstract] [Full Text] [Related]

  • 40. Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live).
    Bernstein HH, Eves K, Campbell K, Black SB, Twiggs JD, Reisinger KS, Conti RM, Flodmark CE, Rombo L, Klopfer S, Schödel F, Hartzel J, Kuter BJ, Refrigerator-Stable Formulation Study Group for ProQuad.
    Pediatrics; 2007 Jun 29; 119(6):e1299-305. PubMed ID: 17502347
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.